#fiercebiotechhomepage — Public Fediverse posts

https://www.europesays.com/ch/139456/ Novartis pays Antares $105M upfront in oncology drug discovery pact worth up to $1.9B #biotech #Deals #FierceBiotechHomepage #Novartis #Oncology #SmallMolecules #UndruggableTargets

https://www.europesays.com/dk/177887/ Novo scraps $285M pact with Ascendis to develop monthly GLP-1 #AscendisPharma #biotech #FierceBiotechHomepage #GLP1 #LicensingDeals #NovoNordisk #Obesity #WeightLoss

https://www.europesays.com/ch/139126/ Genentech CEO on the next 50 years of the original biotech #biotech #ceo #ExecutiveInterview #FierceBiotechHomepage #Genentech #research #Roche #SouthSanFrancisco

Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D

Sanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage immunology programs, teeing the longstanding partners up…
#France #FR #Europe #EU #Sanofi #Biotech #deals #eczema #FierceBiotechHomepage #immunology #Licensingdeals #RegeneronPharmaceuticals
https://www.europesays.com/france/87502/

GSK continues stockpiling Wave drugs with liver-focused program

GSK is paying Wave Life Sciences $12 million upfront to take ownership of a hepatic program arising from…
#EuropeSays #Britain #Europe #EU #GSK #biotech #Drugdeliveryrobot #FierceBiotechHomepage #Licensingdeals #WaveLifeSciences
https://www.europesays.com/britain/134620/

https://www.europesays.com/britain/134620/ GSK continues stockpiling Wave drugs with liver-focused program #biotech #DrugDeliveryRobot #FierceBiotechHomepage #GSK #LicensingDeals #WaveLifeSciences

https://www.europesays.com/ch/138487/ Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program #biotech #ClinicalData #FierceBiotechHomepage #Obesity #ObesityDrugs #Roche #ZealandPharma

https://www.europesays.com/ie/711928/ Novo agrees $2.6B deal for Hengrui’s preclinical GLP-1/GIP drug #biotech #China #Deals #Éire #FierceBiotechHomepage #GLP1 #Health #IE #Ireland #JiangsuHengruiPharmaceuticals #LicensingDeals #Medication #NovoNordisk #Obesity #Type2Diabetes #WeightLoss

Novo agrees $2.6B deal for Hengrui’s preclinical GLP-1/GIP drug

Novo’s ongoing attempts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most…
#NewsBeep #News #Medication #AU #Australia #Biotech #China #Deals #FierceBiotechHomepage #GLP-1 #Health #JiangsuHengruiPharmaceuticals #Licensingdeals #NovoNordisk #Obesity #type2diabetes #WeightLoss
https://www.newsbeep.com/au/909913/

AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combos

AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with…
#EuropeSays #Britain #Europe #EU #AstraZeneca #antibody-drugconjugates #biotech #Deals #drugcombinations #FierceBiotechHomepage #FiercePharmaHomepage #PD-1 #SummitTherapeutics #VEGF
https://www.europesays.com/britain/133635/

https://www.europesays.com/britain/133635/ AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combos #AntibodyDrugConjugates #AstraZeneca #biotech #Deals #DrugCombinations #FierceBiotechHomepage #FiercePharmaHomepage #PD1 #SummitTherapeutics #VEGF

https://www.europesays.com/dk/176054/ Novo agrees $2.6B deal for Hengrui’s preclinical GLP-1/GIP drug #biotech #China #Deals #FierceBiotechHomepage #GLP1 #JiangsuHengruiPharmaceuticals #LicensingDeals #NovoNordisk #Obesity #Type2Diabetes #WeightLoss

BioMarin inks $275M Alesta buyout to challenge AstraZeneca

BioMarin Pharmaceutical has agreed to buy Alesta Therapeutics for $275 million upfront, positioning the biopharma to challenge AstraZeneca for…
#EuropeSays #Britain #Europe #EU #AstraZeneca #BioMarinPharmaceutical #biotech #Deals #FierceBiotechHomepage #mergersandacquisitions #Strensiq
https://www.europesays.com/britain/133263/

https://www.europesays.com/britain/133263/ BioMarin inks $275M Alesta buyout to challenge AstraZeneca #AstraZeneca #BioMarinPharmaceutical #biotech #Deals #FierceBiotechHomepage #MergersAndAcquisitions #Strensiq

https://www.europesays.com/ch/137619/ Roche drops obesity antibody after flunked interim analysis #biotech #Chugai #ClinicalTrialResults #FailedTrials #FierceBiotechHomepage #Obesity #pipeline #Roche

https://www.europesays.com/ch/137417/ Novartis drops ph. 2-stage radioligand therapy over poor data #biotech #FierceBiotechHomepage #Novartis #Oncology #Pluvicto #radiopharmaceuticals

Sanofi-backed Expedition lands $115M for ph. 2 COPD tria

Expedition Therapeutics has secured an oversubscribed $115 million series B financing from a line-up of big-name investors to…
#France #FR #Europe #EU #Sanofi #Biotech #chronicobstructivepulmonarydisease(COPD) #FierceBiotechHomepage #RACapital #seriesB #Sofinnova #venturecapital
https://www.europesays.com/france/85506/

https://www.europesays.com/dk/174869/ Prospects for Novo’s CKD program narrow as ph. 3 trials scrapped #biotech #CardiovascularDisease #FailedTrials #FierceBiotechHomepage #NovoNordisk

AstraZeneca ends phase 3 cancer trial as bispecific underwhelms

AstraZeneca has stopped a phase 3 trial of volrustomig in lung cancer based on interim efficacy data, narrowing the…
#EuropeSays #Britain #Europe #EU #AstraZeneca #biotech #bispecificantibodies #clinicaldata #failedtrials #FierceBiotechHomepage #immuno-oncology #non-smallcelllungcancer
https://www.europesays.com/britain/132372/

https://www.europesays.com/britain/132372/ AstraZeneca ends phase 3 cancer trial as bispecific underwhelms #AstraZeneca #biotech #BispecificAntibodies #ClinicalData #FailedTrials #FierceBiotechHomepage #ImmunoOncology #NonSmallCellLungCancer

https://www.europesays.com/dk/174709/ Novo and AWS sign AI drug discovery pact, launch London hub #AIAndMachineLearning #AmazonWebServices #ArtificialIntelligence #biotech #Deals #DrugDiscovery #FierceBiotechHomepage #NovoNordisk

GSK unveils cost-saving plan to fund R&D, research HQ move

GSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its…
#EuropeSays #Britain #Europe #EU #GSK #AstraZeneca #biotech #Cambridge #FierceBiotechHomepage #HIV #LukeMiels #researchanddevelopment
https://www.europesays.com/britain/132116/

https://www.europesays.com/britain/132116/ GSK unveils cost-saving plan to fund R&D, research HQ move #AstraZeneca #biotech #Cambridge #FierceBiotechHomepage #GSK #HIV #LukeMiels #ResearchAndDevelopment

https://www.europesays.com/ch/136259/ Genentech sees 103 layoffs, pens $490M breast cancer collab #AstexPharmaceuticals #biotech #Deals #FierceBiotechHomepage #Genentech #Layoffs #LicensingDeals #Roche

https://www.europesays.com/dk/174042/ Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables #biotech #ControlledReleaseDrugDelivery #Deals #FierceBiotechHomepage #novo #NovoNordisk #ObesityDrugs #Type2Diabetes

https://www.europesays.com/ch/136069/ Roche’s Genentech inks $1.5B bispecific pact with fast-rising Earendil #AIAndMachineLearning #biotech #BispecificAntibodies #Deals #FierceBiotechHomepage #Genentech #LicensingDeals #Oncology #Roche

Brazil, Korea and UAE all targeting biotech ‘emerging economy’

Whether it’s looming tariff threats or the rise of China as an innovation powerhouse, you need a truly…
#EuropeSays #Korea #KR #SamsungBiologics #abudhabi #biotech #Brazil #FierceBiotechHomepage #Samsung #SouthKorea
https://www.europesays.com/korea/166741/

Sanofi replaces R&D chief as new CEO seeks to kickstart pipeline

Recently appointed Sanofi CEO Belén Garijo has stamped her mark on the organization, hiring former Roche executive Paulo Fontoura,…
#France #FR #Europe #EU #Sanofi #Biotech #ChutesandLadders #Executives #FierceBiotechHomepage #PersonnelAnnouncements #research
https://www.europesays.com/france/83919/

Sanofi won’t seek approval for eczema drug from Kymab buyout

Sanofi has abandoned plans to seek approval for amlitelimab in atopic dermatitis (AD), admitting that a drug once…
#France #FR #Europe #EU #Sanofi #atopicdermatitis #Biotech #eczema #failedtrials #FierceBiotechHomepage
https://www.europesays.com/france/83906/

Sanofi CEO ‘looking deeply’ at pipeline as clearout continues

When Belén Garijo, M.D., Ph.D., left the top job at Germany’s Merck KGaA to head over to Sanofi,…
#France #FR #Europe #EU #Sanofi #BelénGarijo #Biotech #deals #failedtrials #FierceBiotechHomepage #FiercePharmaHomepage
https://www.europesays.com/france/83893/

Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’

Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has…
#France #FR #Europe #EU #Sanofi #Biotech #clinicaltrial #FierceBiotechHomepage #lungdisease #pipeline
https://www.europesays.com/france/83875/

GSK plans phase 3 after mRNA flu vaccine beats standard shots

GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a phase…
#EuropeSays #Britain #Europe #EU #GSK #biotech #clinicaldata #FierceBiotechHomepage #influenzavaccine #mRNA #seasonalinfluenzavaccine
https://www.europesays.com/britain/130899/

https://www.europesays.com/britain/130899/ GSK plans phase 3 after mRNA flu vaccine beats standard shots #biotech #ClinicalData #FierceBiotechHomepage #GSK #InfluenzaVaccine #mRNA #SeasonalInfluenzaVaccine

https://www.europesays.com/britain/130881/ GSK pens $1.3B Hutchmed deal for KRAS-EGFR cancer asset #biotech #BiotechDeals #ColorectalCancer #FierceBiotechHomepage #GSK #Hutchmed #KRAS #NonSmallCellLungCancer

GSK pens $1.3B Hutchmed deal for KRAS-EGFR cancer asset

GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to…
#EuropeSays #Britain #Europe #EU #GSK #biotech #biotechdeals #colorectalcancer #FierceBiotechHomepage #Hutchmed #KRAS #non-smallcelllungcancer
https://www.europesays.com/britain/130881/

GSK’s ADC lays down marker for lung cancer scrap with Merck

GSK’s risvutatug rezetecan (ris-rez) has achieved a median overall survival (OS) of 18.5 months in a phase 3…
#EuropeSays #Britain #Europe #EU #GSK #Amgen #antibody-drugconjugates #biotech #clinicaldata #DaiichiSankyo #FierceBiotechHomepage #HansohPharma #Merck&Co. #smallcelllungcancer #solidtumor
https://www.europesays.com/britain/130843/

https://www.europesays.com/britain/130843/ GSK’s ADC lays down marker for lung cancer scrap with Merck #Amgen #AntibodyDrugConjugates #biotech #ClinicalData #DaiichiSankyo #FierceBiotechHomepage #GSK #HansohPharma #Merck&Co #SmallCellLungCancer #SolidTumor